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A B S T R A C T
 
Background: In 2001, the Brazilian Ministry of Health added hemoglobinopathies to the 
National Neonatal Screening Program to be implemented in three steps. In order to meet 
the proposed goals, it is crucial to establish periodic assessments of this program with the 
aim of monitoring its implementation.
Objective: To assess the scope and the efficiency of the stages of the National Newborn 
Screening Program in identifying hemoglobin S. 
Methods: A cross-sectional study was developed with the results of the heel prick test using 
the high performance liquid chromatography method for babies born in Mato Grosso do Sul 
from 2006 to 2010. The following variables were investigated: year, number of live births, 
total screening, coverage ratio, prevalence, time between the child birth and the blood 
collection; age at diagnosis; age at the time of the first consultation; and time between the 
diagnosis and the first appointment. 
Results: Over the five years of the study, the mean coverage rate was 91.77%. The prevalences 
of hemoglobin FAS and hemoglobin FS were 1.65% and 0.011%, respectively. Blood samples 
from 43.48% of children were collected from the second to the seventh day. The age at 
diagnosis was within the first 28 days in 87.80% of the screened children. The lowest 
mean indices for the first consultation and the time between the diagnosis and the first 
appointment (58.8 and 46.4 days, respectively) occurred in 2010. 
Conclusions: The scope of the National Neonatal Screening Program for hemoglobinopathies 
is good, with a large number of individuals being tested. Efficiency is a suitable indicator to 
assess the program steps. Three points are recommended: the training of the individuals 
involved, studies to assess the assistance provided to the affected child, and genetic 
counseling to the mothers.
© 2014 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. All rights 
reserved.
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Introduction
Hemoglobinopathies are recessively inherited genetic diseases, 
including sickle cell disease and thalassemias.1 The presence 
of hemoglobin S (Hb S), prevailing in sickle cell disease, 
consists in a change that characterizes it as a structural 
hemoglobinopathy, whereas thalassemia is a synthesis 
hemoglobinopathy. Individuals with Hb S have predominated 
in the screenings performed in the state of Mato Grosso do Sul 
(MS).2,3 In order to explain these findings, further research is 
needed. However, this study corroborates research developed 
in Dourados, MS, using molecular biology techniques to 
confirm the diagnosis of some hemoglobinopathies.4
Hb S can be found in the heterozygous state (sickle cell trait), 
which is considered asymptomatic, that is without disease; 
in a homozygous state (Hb SS or sickle cell anemia), or in 
association with other changes (Hb S/β-thalassemia, Hb SC, HB 
SD and others).5,6 Because of the clinical complexity and high 
death rate worldwide, these genetic changes, specifically sickle 
cell anemia, have contributed to the creation of community-
based programs.7
In 2001, the Brazilian Ministry of Health, through the Act 
822/01, added the hemoglobinopathies to the National Neonatal 
Screening Program (Programa Nacional de Triagem Neonatal) to be 
implemented in three steps in 12 Brazilian States.8 Under the 
responsibility of the Instituto de Pesquisas, Ensino e Diagnóstico 
da Associação de Pais e Amigos dos Excepcionais (IPED-APAE), the 
program is in its Step II in the State of Mato Grosso do Sul. 
Coverage has been increasing in the State; in 2002, the program 
already screened 92.06% of newborns.2 Since then, there have 
been no records of coverage of less than 87.41%.2
For the screening program to be able to reach the proposed 
goals,8 it is essential to establish periodic assessments, and 
divulge the results to the public health authorities intending 
to improve the system. The assessment of the scope and the 
efficiency of the program leads to its monitoring, aiming at 
better meeting the population´s needs.9 Accordingly, this study 
aims not only at assessing the comprehensiveness (coverage) 
of the program, but also at identifying the steps (efficiency) 
that need to be improved. Thus, the efficiency of the steps of 
the screening program was chosen as an appraisal indicator. 
The objective of this work was to assess the scope and the 
efficiency of the steps of the hemoglobin S screening program 
in the State of Mato Grosso do Sul, from 2006 to 2010.
Methods
This is a cross-sectional study of the screening results for 
hemoglobinopathies of 181,973 children in the 78 municipalities 
of the State of Mato Grosso do Sul. Information was obtained 
from 923 registered collection stations of the screening 
program − IPED-APAE in the period from 2006 to 2010.
The variables studied to assess the scope were: year, number 
of live births,10 total screening, coverage rate, and prevalence 
of hemoglobinopathies, with the exception of thalassemia.
The variables studied to analyze the efficiency of the 
program were: the time between the child´s birth and the 
exam, the age at diagnosis, the child´s age at the time of the 
first consultation, and the time between the diagnosis and the 
first appointment. This study focused on sickle cell diseases 
as this proved to be the most common hemoglobinopathies.
The date of the first consultation was taken from the records 
of IPED-APAE. The time between the diagnosis and the first 
appointment was calculated from the date of the diagnosis, 
and from the date of the first consultation.
The screening steps at IPED-APAE are performed in accordance 
with the technical criteria defined in the Manual of Technical 
Standards and Operational Routines of the screening program.8
The process starts with blood collection for tests on filter 
paper (Schleicher & Schuell 903), using the heel prick technique 
in Family Health Clinics, maternity wards or hospitals, by a 
member of the nursing team or a trained technician.
After collecting and drying the sample, it is placed in 
an envelope for biological materials and sent to a testing 
laboratory. Municipalities with ambulances going to Campo 
Grande (the State capital) ship the samples directly to the 
screening laboratory for newborn diseases.
In the laboratory, the blood samples are classified in respect 
to the quality of the blood sample, and the data relating to the 
age of the child at the time of the collection is recorded. The 
criteria adopted to discard the blood sample are: unsuitable 
sample (visual), insufficient blood for all tests, and early 
sample (obtained within the first 48 hours after birth). Samples 
discarded due to the above criteria are returned to the place of 
origin for the collection of another sample. This study included 
valid samples only.
Hemoglobin screening is performed using the VARIANTnbs 
High Performance Liquid Chromatography (HPLC) system. This 
is a qualitative screening that identifies the presence of normal 
(Hb F and A) and abnormal hemoglobins (Hb S, D, C, and E). 
This methodology is recognized as the gold standard by 
the Brazilian Ministry of Health. The results of the tests are 
available as web reports sent to the health clinics via the 
internet, printed, or sent by e-mail. 
Newborns with results suggestive of hemoglobinopathies 
are scheduled for their first consultation with a hematologist 
at APAE-IPED. Subsequently, a clinical follow-up is carried out 
during the first year of life, and after this period the children 
are referred to the Campo Grande Regional Hospital to confirm 
the diagnosis.
This research was approved by the Research Ethics 
Committee of the Universidade Federal de Mato Grosso do 
Sul (protocol #1.822/2010/UFMS). For the statistical analysis, 
descriptive measures were calculated using the Statistical 
Analysis Software (SAS) version 9.0 for Windows. The following 
formula was used to calculate the coverage of the screening 
program: coverage = number of screened babies / number of 
live births × 100. Prevalence rates were estimated by point and 
95% confidence intervals (95% CI).
Results
Based on the number of live births, the coverage rate varied 
over the five-year period (Table 1); the highest coverage 
occurred in 2006 (94.26%), and the lowest in 2010 (89.69%).
Of the total of 181,973 samples screened by the program, 3,040 
were diagnosed with Hb S in different genotypic associations; 
20 cases were diagnosed with Hb FS; eight had results for Hb 
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FSC, one for Hb FSD, and 3,011 were Hb FAS, the asymptomatic 
form of the disease.
When examining the prevalence among 181,973 
children screened (Table 2), Hb S was the most frequent 
hemoglobinopathy, with Hb FAS being the most prevalent 
in 2007. The prevalence of the homozygous form, sickle cell 
anemia, was 0.011% with one case in 9,098 children screened.
before 48 hours of life; 1,322 (43.48%), between the second and 
seventh day, and 1,401 (46.1%), between the eighth and 30th 
day. A further 46 (1.5%) children presented positive results for 
Hb FAS, yet there was no record of their age at the time of 
collection.
  
Year 
 
Live birth (n)
Screened 
newborns (n)
Coverage  
rate (%)
2006   39,309   37,054 94.26
2007   38,378   34,824 90.74
2008   41,045   37,693 91.83
2009   39,979   36,898 92.29
2010   39,587   35,504 89.69
Total 198,298 181,973 91.77
IPED-APAE: Instituto de Pesquisas, Ensino e Diagnósticos da 
Associação de Pais e Amigos dos Excepcionais. 
Table 1 - Overall screenings and coverage rate of 
newborns investigated at IPED
APAE, Mato Grosso do Sul, 2006 to 2010.
In respect to the time from birth to the blood sampling 
for neonatal screening, Table 3 shows that, of the children 
screened with hemoglobin S, 161 (5.3%) underwent the test 
Hemo-
globi- 
nopathy 
  
 
Year
Children 
screened 
n
 
Cases 
n
Preva- 
lence  
(%)a
 
  
95% CIb 
Hb FAS 2006   37,054 625 1.687 1.655-
1.719
2007   34,824 652 1.872 1.830-
1.917
2008   37,693 598 1.587 1.550-
1.624
2009   36,898 508 1.377 1.343-
1.411
2010   35,504 628 1.769 1.724-
1.814
All 181,973 3,011 1.655 1.636-
1.671
Hb FS All 181,973 20 0.011 0.0096-
0.012
Hb FSC All 181,973 8 0.0044 0.0035- 
0.0056
Hb FSD All 181,973 1 0.0006 0.0002- 
0.0013
a Estimates of prevalence rate by point.  
b Estimates of prevalence by confidence level of 95%.
Table 2 - Prevalence of hemoglobinopathies estimated 
as percentages of total and 95% confidence interval in 
children screened at IPED-APAE, Mato Grosso do Sul, 
2006 to 2010. Data related to the occurrence of cases of sickle cell trait 
and sickle cell disease, according to age in days at the time of 
diagnosis, indicate that among the children screened, 2,669 
were between 0 and 28 days at diagnosis, and 371 were older. 
Among the newborns, 24 had sickle cell disease genotypes (18 
with Hb FS, five with Hb FSC, and one with Hb FSD), and 2,645 
had the sickle cell trait genotype (Hb FAS).
Among the children older than 28 days at diagnosis, five 
cases had the disease (two with Hb FS, and three with Hb FSC), 
and 366 had Hb FAS.
As for the age of children at the time of the first 
appointment, in 2009, the mean age was 112.3 days (n = 7; 
median = 81; range: 50-217 days), whereas in 2010, there was 
a decrease in age at the first consultation, with a mean of 58.8 
days (n = 8; median = 40.5; range: 31-148 days) (Table 4).
 
Age 
days 
  
Hb FAS  
n
 
Hb FS 
n
 
Hb FSC 
n
 
Hb FSD 
n
  
 
Total 
0-1 160 1 0 0 161
2-7 1,307 9 5 1 1,322
8-30 1,390 10 1 0 1,401
31-60 91 0 1 0 92
61-90 7 0 0 0 7
91-100 2 0 1 0 3
101-200 4 0 0 0 4
201-300 3 0 0 0 3
> 300 1 0 0 0 1
No records 46 0 0 0 46
Total 3,011 20 8 1 3,040
Table 3 - Occurrence of cases of sickle cell trait and 
sickle cell disease according to age in days at time of 
sample collection for neonatal screening at IPED-APAE, 
Mato Grosso do Sul, 2006 to 2010.
Year n Mean Median Minimum Maximum 
2006 8 110.4 97 61 201
2007 5 68.6 4 23 146
2008 1 71.0 71 71 71
2009 7 112.3 81 50 217
2010 8 58.8 40.5 31 148
Table 4 - Age of the children in days, at time of the first 
consultation after diagnosis in the neonatal screening 
program at IPED-APAE, Mato Grosso do Sul, 2006 to 
2010.
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The highest mean number of days between the diagnosis of 
sickle cell disease and the first consultation was in 2006 (n = 
8; mean: 86.8; median = 63.5; range: 50-154 days). In 2010, the 
average number of days between the diagnosis and the first 
appointment was the lowest (n = 8; mean: 46.4; median = 28; 
range: 4-135 days).
Discussion
The mean coverage of screening program in this study was 
91.77% between 2006 and 2010, with the highest rate in 2006 
(94.26%). In a study conducted in the Brazilian Federal District, the 
coverage rate was 83.4% in 2006,11 and in Bahia State, the average 
coverage rate was 88.9% in the period from 2007 to 2009.12 The 
program´s national goal is to achieve a coverage of 100%.8
The differences among the Brazilian regions can be justified 
by the structure and the organization of services. The uptake of 
live births, the number of collection stations, the shipment of 
samples in a suitable timeframe, and the articulation between 
the steps, are of utmost importance for the program’s success. 
As for the equity of access, the local services should be aware 
of niche populations, because of the risk of failing to collect 
samples given the cultural, social, and economic heterogeneity 
of Mato Grosso do Sul, which borders Bolivia and Paraguay, and 
has the second largest indigenous population in the country.13
Regarding the prevalence of the hemoglobinopathies, the 
results show that, of 181,973 children screened, 3,040 (1.67%) 
presented Hb S in different genotypic associations.
This finding confirms those described in the literature, i.e., 
in Brazil, Hb S is the commonest hemoglobinopathy, marked 
by a high prevalence, and potential morbidity.14 These results 
corroborate the epidemiological survey developed in Mato 
Grosso do Sul, from 2000 to 2005, in which, among the children 
screened, 2,624 (1.38%) presented Hb S in different genotypic 
associations.2
In the present study, the highest prevalence for Hb FAS was 
1.87% in 2007. This finding places Mato Grosso do Sul, together 
with Santa Catarina (0.9%),15 among the Brazilian states with 
the lowest prevalence of sickle cell disease. These results are 
different from those of Bahia, which presented one case for 
every 650 live births screened (n = 257); Bahia is the State with 
the highest prevalence of sickle cell disease.16
Attention should be paid to the results related to the time 
between the birth and neonatal screening, which revealed 
early collections in 5.3% of the cases. In Brazil, the Ministry 
of Health reported that, in 2011; 62.11% of the tests were 
performed by the seventh day of life, disregarding the results 
in cases of early collection.17
When analyzing the age in days at the time of collection, it 
was found that 43.48% occurred from the second to seventh 
day, as recommended by the screening program.8
Globally, the results of studies in respect to the age at the 
time of collection are fairly diversified. Research conducted in 
the Gaza Strip, in the Palestinian Territories, showed that 61% 
of the collections occurred between the 11th and 17th day of 
life.18 In Brazil, in Porto Alegre city, the average was 11 days;19 
in Sergipe State 17 days, with 50% of samples being collected 
in children older than 28 days;20 in Campina Grande city, the 
average was 29.8 days,21 and in Marília, São Paulo State, the 
average was 27 days.22
A weak point in this study lies in the absence of a record 
of the age at the time of collection for 46 children positive for 
Hb FAS.
Concerning the age in days at diagnosis, 87.80% of the 
results were ready while the subjects were neonates (up to 
28 days). In discussing this figure, it was observed that early 
diagnosis favors interventions and, therefore, positively 
influences the outcome of the disease.23 
In recent years, the expectations related to morbidity and 
mortality from sickle cell disease have changed dramatically, 
partly due to the higher accuracy of tests, early diagnosis, 
and greater knowledge about the disease. Another reason is 
the increased sensitivity of the public health institutions in 
Brazil, motivated by social movements focused on the black 
population, and by the societies of Hb S gene carriers.5
Regarding the age of the child at the first consultation, and 
the time between the diagnosis and the first appointment, 2010 
had the lowest indices among the years studied, which led to 
a shorter time to diagnosis. According to the literature, the 
earlier the diagnosis and treatment of sickle cell disease, the 
less likely patients will have complications, thereby increasing 
the survival and the quality of life.24
Routine preventive measures for patients with sickle 
cell disease should be initiated within the first two months 
of life, as at the first consultation; parents and guardians 
should be counseled about prophylaxis against infections, 
immunizations, and also taught to identify the complications 
of the disease, reducing morbidity and mortality.25
The screening program defines the intervals between the 
steps, so as to provide the patient with early diagnosis and 
timely treatment. Therefore, the gap between the birth and 
the initiation of the treatment should be short, so that the 
program can be effective in preventing sequels, in promoting 
social inclusion, and in reducing suffering.23
Conclusion
The scope of the screening program for hemoglobinopathies 
in the state of Mato Grosso do Sul is successful, with a mean 
coverage of 91.77%, thereby providing diagnoses of Hb S for 
the population. Efficiency, the indicator employed in this 
study, identified two steps that need to be improved: the time 
of the sample collection, which in many cases is too early, 
and age at diagnosis of more than 28 days. Thus, the authors 
of this study would like to make three recommendations: 
continuous training of those involved, further studies to assess 
the assistance provided to affected children, and the provision 
of genetic counseling to mothers.
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